Nausea gets a warning on every intake form. A hoarse voice and a persistent cough do not, and a retrospective cohort using a large US network looked at whether they should[1]. Adults with obesity on these drugs were matched to controls on age, sex, race and ethnicity, with anyone carrying head and neck cancer, prior radiation, autoimmune disease or airway disorders excluded first.
Within six months of starting, any laryngeal symptom was more likely at an odds ratio of 1.19 (95% CI 1.16–1.21). Cough came in highest at 1.46, and voice and resonance disorders at 1.19. Exenatide, liraglutide, semaglutide, dulaglutide and lixisenatide each showed a significant six-month elevation; tirzepatide and albiglutide did not. Keeping the molecules straight matters here for the same reason it does in the super-responder brand comparison.
The obvious candidate explanation is reflux, which these drugs are separately associated with, and which classically presents as throat clearing, a lump-in-the-throat sensation and a cough rather than heartburn. This study measured none of that — no pH testing, no endoscopy, no reflux diagnosis in the analysis — so the connection is a hypothesis rather than a finding. The stomach-side effects these drugs are known for are covered in the pooled gallstone and reflux figures, which have the trial denominators this design lacks.
Two drugs not reaching significance complicates any class-wide story, though it is worth noting that a drug with fewer users has less statistical power, and albiglutide has been off the market for years. Tirzepatide is a different case: it is widely used, so its null result is more informative than albiglutide's, and it is the second of two recent comparisons where tirzepatide separated from the older drugs on an unexpected endpoint.
The practical reading for a buyer is narrow and cheap to act on. If a cough or a change in your voice starts within a few months of beginning one of these drugs, it is worth mentioning rather than assuming it is unrelated, and it is the kind of thing a thorough intake would ask about at follow-up. How much follow-up a seller actually provides varies more than the prices do, which is the thread running through sellers publishing two prices and what a GLP-1 actually costs.